Cat.No：GM-87836MAB
Product ：Anti-CTLA4×PD-1 hIgG1 Reference Antibody (Cadbio)
Cat.No：GM-87836MAB
Product ：Anti-CTLA4×PD-1 hIgG1 Reference Antibody (Cadbio)
GM-87836MAB-1mg / 1 mg
GM-87836MAB-5mg / 5 mg
GM-87836MAB-25mg / 5 mg * 5 vials
GM-87836MAB-50mg / 50 mg
GM-87836MAB-100mg / 50 mg * 2 vials
Expression System | CHO |
Aggregation | < 5% as determined by SEC-HPLC |
Purity | > 95% as determined by SDS-PAGE |
Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
Sterility | 0.2 μm Filtered |
Target | CTLA4&PD-1 |
Clone | Cadonilimab |
Alternative Names | CTLA4: ALPS5,CD,CD152,CELIAC3,CTLA-4,GRD4, GSE, IDDM12 PD1: CD279, PD-1, PDCD1, SLEB2, hPD-1, hPD-l, hSLE1 |
Source/Isotype | Monoclonal Human IgG1 L234A/L235A, Kappa |
Application | Bioactivity-ELISA |
Description | Cadonilimab antagonizes CTLA-4, preventing T cells from binding to its ligands, thereby alleviating immune suppression and promoting T cell activation. At the same time, Cadonilimab targets PD-1, blocking its interactions with PD-L1 and PD-L2, which relieves the inhibition on T cells and further enhances their anti-cancer activity. By simultaneously targeting both CTLA-4 and PD-1, Cadonilimab can activate T cells more comprehensively, significantly boosting the immune response against tumors. |
Formulation | phosphate-buffered solution, pH 7.2-7.4. |
Cat.No：GM-87836MAB
Product ：Anti-CTLA4×PD-1 hIgG1 Reference Antibody (Cadbio)
GM-87836MAB-1mg / 1 mg
GM-87836MAB-5mg / 5 mg
GM-87836MAB-25mg / 5 mg * 5 vials
GM-87836MAB-50mg / 50 mg
GM-87836MAB-100mg / 50 mg * 2 vials
Expression System | CHO |
Aggregation | < 5% as determined by SEC-HPLC |
Purity | > 95% as determined by SDS-PAGE |
Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
Sterility | 0.2 μm Filtered |
Target | CTLA4&PD-1 |
Clone | Cadonilimab |
Alternative Names | CTLA4: ALPS5,CD,CD152,CELIAC3,CTLA-4,GRD4, GSE, IDDM12 PD1: CD279, PD-1, PDCD1, SLEB2, hPD-1, hPD-l, hSLE1 |
Source/Isotype | Monoclonal Human IgG1 L234A/L235A, Kappa |
Application | Bioactivity-ELISA |
Description | Cadonilimab antagonizes CTLA-4, preventing T cells from binding to its ligands, thereby alleviating immune suppression and promoting T cell activation. At the same time, Cadonilimab targets PD-1, blocking its interactions with PD-L1 and PD-L2, which relieves the inhibition on T cells and further enhances their anti-cancer activity. By simultaneously targeting both CTLA-4 and PD-1, Cadonilimab can activate T cells more comprehensively, significantly boosting the immune response against tumors. |
Formulation | phosphate-buffered solution, pH 7.2-7.4. |
